rosiglitazone has been researched along with Anochlesia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| David, SR; Gupta, G; Singh, R; Verma, RK | 1 |
| Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N | 1 |
2 other study(ies) available for rosiglitazone and Anochlesia
| Article | Year |
|---|---|
Effect of rosiglitazone, a PPAR-γ ligand on haloperidol-induced catalepsy.
Topics: Animals; Catalepsy; Haloperidol; Hypoglycemic Agents; Ligands; Male; Mice; Oxidative Stress; PPAR gamma; Rosiglitazone; Scopolamine; Superoxide Dismutase; Thiazolidinediones | 2013 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liquid; Chronic Disease; Disease Models, Animal; Dopamine; Drug Interactions; Dynorphins; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Globus Pallidus; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; PPAR gamma; Psychomotor Performance; RNA, Messenger; Rosiglitazone; Smell; Tandem Mass Spectrometry; Thiazolidinediones; Tyrosine 3-Monooxygenase | 2009 |